BrainStorm Cell Therapeutics Inc. (BCLI) stock
BCLIOTCBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$0.77−0.01 (-1.17%)
Close on Oct 19, 2026Market cap $8.50MP/E –Yield –
BrainStorm Cell Therapeutics operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
BrainStorm Cell Therapeutics's operating income for the twelve months ending Jun 30, 2026 was -$9.95M. For fiscal 2025 it was -$9.95M. The highest annual figure on record is $2.40M in fiscal 2010.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$9.95M | – |
| FY2024 | Dec 31, 2024 | -$11.69M | – |
| FY2023 | Dec 31, 2023 | -$21.44M | – |
| FY2022 | Dec 31, 2022 | -$24.82M | – |
| FY2021 | Dec 31, 2021 | -$24.54M | – |
| FY2020 | Dec 31, 2020 | -$31.68M | – |
| FY2019 | Dec 31, 2019 | -$23.00M | – |
| FY2018 | Dec 31, 2018 | -$14.06M | – |
| FY2017 | Dec 31, 2017 | -$5.00M | – |
| FY2016 | Dec 31, 2016 | -$5.08M | – |
| FY2015 | Dec 31, 2015 | -$8.54M | – |
| FY2014 | Dec 31, 2014 | -$7.42M | – |
| FY2013 | Dec 31, 2013 | -$4.90M | – |
| FY2012 | Dec 31, 2012 | -$3.43M | – |
| FY2011 | Dec 31, 2011 | -$3.91M | -263.0% |
| FY2010 | Dec 31, 2010 | $2.40M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$3.61M | – |
| Q1 FY2026 | Mar 31, 2026 | -$2.05M | – |
| Q4 FY2025 | Dec 31, 2025 | -$2.24M | – |
| Q3 FY2025 | Sep 30, 2025 | -$2.05M | – |
| Q2 FY2025 | Jun 30, 2025 | -$2.57M | – |
| Q1 FY2025 | Mar 31, 2025 | -$3.09M | – |
| Q4 FY2024 | Dec 31, 2024 | -$3.19M | – |
| Q3 FY2024 | Sep 30, 2024 | -$3.05M | – |
| Q2 FY2024 | Jun 30, 2024 | -$2.98M | – |
| Q1 FY2024 | Mar 31, 2024 | -$2.47M | – |
| Q4 FY2023 | Dec 31, 2023 | -$4.80M | – |
| Q3 FY2023 | Sep 30, 2023 | -$6.04M | – |
| Q2 FY2023 | Jun 30, 2023 | -$5.45M | – |
| Q1 FY2023 | Mar 31, 2023 | -$5.15M | – |
| Q4 FY2022 | Dec 31, 2022 | -$4.92M | – |
| Q3 FY2022 | Sep 30, 2022 | -$6.84M | – |
| Q2 FY2022 | Jun 30, 2022 | -$7.59M | – |
| Q1 FY2022 | Mar 31, 2022 | -$5.48M | – |
| Q4 FY2021 | Dec 31, 2021 | -$6.21M | – |
| Q3 FY2021 | Sep 30, 2021 | -$5.28M | – |
| Q2 FY2021 | Jun 30, 2021 | -$6.12M | – |
| Q1 FY2021 | Mar 31, 2021 | -$6.93M | – |
| Q4 FY2020 | Dec 31, 2020 | -$11.49M | – |
| Q3 FY2020 | Sep 30, 2020 | -$4.49M | – |
| Q2 FY2020 | Jun 30, 2020 | -$7.40M | – |
| Q1 FY2020 | Mar 31, 2020 | -$8.31M | – |
| Q4 FY2019 | Dec 31, 2019 | -$7.67M | – |
| Q3 FY2019 | Sep 30, 2019 | -$5.55M | – |
| Q2 FY2019 | Jun 30, 2019 | -$4.86M | – |
| Q1 FY2019 | Mar 31, 2019 | -$4.93M | – |
| Q4 FY2018 | Dec 31, 2018 | -$5.44M | -2384.5% |
| Q3 FY2018 | Sep 30, 2018 | -$3.23M | – |
| Q2 FY2018 | Jun 30, 2018 | -$3.09M | – |
| Q1 FY2018 | Mar 31, 2018 | -$2.31M | – |
| Q4 FY2017 | Dec 31, 2017 | $238.00K | – |
| Q3 FY2017 | Sep 30, 2017 | -$2.39M | – |
| Q2 FY2017 | Jun 30, 2017 | -$1.08M | – |
| Q1 FY2017 | Mar 31, 2017 | -$1.77M | – |
| Q4 FY2016 | Dec 31, 2016 | -$650.00K | – |
| Q3 FY2016 | Sep 30, 2016 | -$1.64M | – |
See a number that looks wrong?